Are Novel Serum Biomarkers Informative?

Medical Clinics of North America

Volumn 96, Issue 1, 2012, Pages 1-11

  Wilkins, John T ^a   Lloyd Jones, Donald M ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Coronary heart disease risk; Risk assessment; Serum biomarkers

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; APOLIPOPROTEIN B; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CYSTATIN C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; TROPONIN I; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

AGE; ANTIHYPERTENSIVE THERAPY; CALIBRATION; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL DECISION MAKING; FRAMINGHAM RISK SCORE; HUMAN; ISCHEMIC HEART DISEASE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; REVIEW; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SEX DIFFERENCE; SMOKING; SYSTOLIC BLOOD PRESSURE;

APOLIPOPROTEIN B-100; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CORONARY DISEASE; DISEASE MANAGEMENT; HUMANS; LIPOPROTEIN(A); MODELS, STATISTICAL; RISK ASSESSMENT; RISK FACTORS; ROC CURVE; SECONDARY PREVENTION; TROPONIN I;

EID: 84857697640     PISSN: 00257125     EISSN: 15579859     Source Type: Journal    
DOI: 10.1016/j.mcna.2012.01.017     Document Type: Review

References (29)

1. Murray C.J., Lopez A.D. Alternative projections of mortality and disability by cause 1990-2020: global burden of disease study. Lancet 1997, 349:1498-1504.
2. Natural history of aortic and coronary atherosclerotic lesions in youth. Findings from the PDAY Study. Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Arterioscler Thromb 1993, 13(9):1291-1298.
3. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Circulation 2002, 106:3143-3421.
4. Wilson P.W., D'Agostino R.B., Levy D., et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998, 97(18):1837-1847.
5. Wilson P.W. Challenges to improve coronary heart disease risk assessment. JAMA 2009, 302(21):2369-2370.
6. D'Agostino R.B., Grundy S.M., Sullivan L.M., et al. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA 2001, 286:180-187.
7. Rose G. Sick individuals and sick populations. Int J Epidemiol 1985, 14(1):32-38.
8. Greenland P., Knoll M.D., Stamler J., et al. Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. JAMA 2003, 290(7):891-897.
9. Zethelius B., Berglund L., Sundström J., et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med 2008, 358(20):2107-2116.
10. Ridker P.M., Buring J.E., Rifai N., et al. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the reynolds risk score. JAMA 2007, 297(6):611-619.
11. Ridker P.M., Cook N. Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham risk scores. Circulation 2004, 109(16):1955-1959.
12. Ridker P.M., Hennekens C.H., Buring J.E., et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000, 342(12):836-843.
13. Buckley D.I., Fu R., Freeman M., et al. C-reactive protein as a risk factor for coronary heart disease: a systematic review and meta-analysis for the U.S. Preventive Services Task Force. Ann Intern Med 2009, 151:483-495.
14. Ridker P.M., Danielson E., Fonseca F.A., et al. Rosuvastatin to prevent vascular events in men and women with elevated c-reactive protein. N Engl J Med 2008, 359(21):2195-2207.
15. Skalen K., Gustafsson M., Rydberg E.K., et al. Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature 2002, 417(6890):750-754.
16. Walldius G., Jungner I., Holme I., et al. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001, 358(9298):2026-2033.
17. Gotto A.M., Whitney E., Stein E.A., et al. Relation Between Baseline and On-Treatment Lipid Parameters and First Acute Major Coronary Events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation 2000, 101(5):477-484.
18. The Emergency Risk Factors Collaboration, Di Angelantonio E., Sarwar N., et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009, 302(18):1993-2000.
19. Sniderman A.D., Williams K., Contois J.H., et al. A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circ Cardiovasc Qual Outcomes 2011, 4(3):337-345.
20. Ingelsson E., Schaefer E.J., Contois J.H., et al. Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. JAMA 2007, 298(7):776-785.
21. Kathiresan S., Otvos J.D., Sullivan L.M., et al. Increased small low-density lipoprotein particle number. Circulation 2006, 113(1):20-29.
22. Bennet A., Di Angelantonio E., Erqou S., et al. Lipoprotein(a) levels and risk of future coronary heart disease: large-scale prospective data. Arch Intern Med 2008, 168(6):598-608.
23. Bostom A., Cupples L., Jenner J., et al. Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 year and younger. A prospsective study. JAMA 1996, 276(7):544-548.
24. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 2009, 302(4):412-423. The Emerging Risk Factors Collaboration.
25. Utermann G., Menzel H.J., Kraft H.G., et al. Lp(a) glycoprotein phenotypes. Inheritance and relation to Lp(a)-lipoprotein concentrations in plasma. J Clin Invest 1987, 80(2):458-465.
26. Omland T., de Lemos J.A., Sabatine M.S., et al. A sensitive cardiac troponin T assay in stable coronary artery disease. N Engl J Med 2009, 361(26):2538-2547.
27. Saunders J.T., Nambi V., de Lemos J.A., et al. Cardiac troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the atherosclerosis risk in communities study/clinical perspective. Circulation 2011, 123(13):1367-1376.
28. deFilippi C.R., de Lemos J.A., Christenson R.H., et al. Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults. JAMA 2010, 304(22):2494-2502.
29. de Lemos J.A., Drazner M.H., Omland T., et al. Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. JAMA 2010, 304(22):2503-2512.